​

Fate Therapeutics Ownership | Who Owns Fate Therapeutics?

OverviewForecastRevenueFinancialsChart

Fate Therapeutics Ownership Summary

Fate Therapeutics is owned by 60.12% institutional investors, 1.07% insiders, and 38.82% retail investors. Redmile group is the largest institutional shareholder, holding 10.72% of FATE shares. BB Biotech AG Ord is the top mutual fund, with 4.25% of its assets in Fate Therapeutics shares.

FATE Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockFate Therapeutics60.12%1.07%38.82%
SectorHealthcare Stocks 244.59%12.11%-156.70%
IndustryBiotech Stocks 379.61%11.70%-291.31%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Redmile group12.87M10.72%$34.76M
Blackrock10.12M10.01%$33.18M
Boxer capital8.22M8.13%$26.95M
Vanguard group8.97M7.54%$8.82M
Wilshire advisors8.49M7.16%$10.69M
Blackrock funding, inc. /de7.30M6.08%$19.71M
Vanguard capital management4.45M3.70%$12.00M
Acadian asset management4.35M3.63%$11.74M
Aqr capital management3.84M3.20%$10.36M
Two sigma investments, lp3.59M2.99%$9.69M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Wilshire advisors8.49M27.71%$10.69M
Redmile group12.87M2.33%$34.76M
Boxer capital8.22M1.42%$26.95M
Johnson & johnson3.38M1.14%$9.12M
Bruce989.19K0.72%$2.67M
Dafna capital management525.00K0.27%$1.42M
Privium fund management b.v.414.31K0.21%$1.12M
Schulhoff100.00K0.11%$270.00K
Artal group1.03M0.09%$3.39M
Headlands251.80K0.07%$679.87K

Top Buyers

HolderShares% AssetsChange
Wilshire advisors8.49M27.71%8.49M
Millennium management2.43M0.00%2.43M
T. rowe price investment management1.08M0.00%1.08M
Blackrock10.12M0.00%1.02M
Aqr capital management3.84M0.00%835.71K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---5.57M
Bellevue group---4.84M
Deerfield management company, l.p. (series c)---3.56M
Ecor1 capital---3.05M
Blackrock funding, inc. /de7.30M0.00%-2.77M

New Positions

HolderShares% AssetsChangeValue
T. rowe price investment management1.08M0.00%1.08M$2.92M
Sixth street partners management company610.95K0.00%610.95K$1.65M
Qube research578.15K0.00%578.15K$1.56M
Marshall wace, llp492.43K0.00%492.43K$1.33M
Susquehanna portfolio strategies338.06K0.01%338.06K$912.76K

Sold Out

HolderChange
Mather group, llc.-5.00
Innealta capital-9.00
Chris bulman-10.00
Turning point benefit group-14.00
Nelson, van denburg & campbell wealth management group-17.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 2026161-72,161,299-2.61%601.58%887.32%3815.15%
Mar 31, 20261587.48%74,066,1332.68%621.70%7850.00%34-35.85%
Dec 31, 202593-34.51%44,014,816-45.32%360.80%31-53.03%31-18.42%
Sep 30, 2025135-3.57%79,628,3630.09%671.49%62-12.68%36-12.20%
Jun 30, 20251384.55%79,496,955-17.58%671.01%7022.81%40-2.44%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
BB Biotech AG Ord4.84M4.25%-
Vanguard Total Stock Mkt Idx Inv3.19M2.74%220.30K
Vanguard Morn Total Stk Mkt Idx Investor3.19M2.74%220.30K
Vanguard MStar Total Stk Mkt Idx Invest3.19M2.74%-
Vanguard Strategic Equity Inv3.12M2.68%583.72K
Vanguard US Total Market Shares ETF3.05M2.66%-
iShares Russell 2000 ETF2.59M2.22%23.92K
SPDR® S&P Biotech ETF2.34M2.06%33.31K
BlackRock Advantage Small Cap Core Instl1.57M1.35%-35.07K
Vanguard Explorer Inv1.27M1.11%-

Recent Insider Transactions

DateNameRoleActivityValue
Aug 04, 2026TAHL CINDY See RemarksSell$95.41K
Aug 04, 2026Valamehr Bahram President and CEOSell$108.10K
May 20, 2026TAHL CINDY See RemarksSell$48.08K
May 20, 2026Valamehr Bahram President and CEOSell$54.48K
Jan 09, 2026TAHL CINDY See RemarksSell$11.28K

Insider Transactions Trends

DateBuySell
2026 Q3-2
2026 Q2-2
2026 Q1-2
2025 Q4--
2025 Q3-2

FATE Ownership FAQ

Who Owns Fate Therapeutics?

Fate Therapeutics shareholders are primarily institutional investors at 60.12%, followed by 1.07% insiders and 38.81% retail investors. The average institutional ownership in Fate Therapeutics's industry, Biotech Stocks , is 379.61%, which Fate Therapeutics falls below.

Who owns the most shares of Fate Therapeutics?

Fate Therapeutics’s largest shareholders are Redmile group (12.87M shares, 10.72%), Blackrock (10.12M shares, 10.01%), and Boxer capital (8.22M shares, 8.13%). Together, they hold 28.86% of Fate Therapeutics’s total shares outstanding.

Does Blackrock own Fate Therapeutics?

Yes, BlackRock owns 10.01% of Fate Therapeutics, totaling 10.12M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 33.18M$. In the last quarter, BlackRock increased its holdings by 1.02M shares, a 11.17% change.

Who is Fate Therapeutics’s biggest shareholder by percentage of total assets invested?

Wilshire advisors is Fate Therapeutics’s biggest shareholder by percentage of total assets invested, with 27.71% of its assets in 8.49M Fate Therapeutics shares, valued at 10.69M$.

Who is the top mutual fund holder of Fate Therapeutics shares?

BB Biotech AG Ord is the top mutual fund holder of Fate Therapeutics shares, with 4.25% of its total shares outstanding invested in 4.84M Fate Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools